Following 2019 rejection, FDA adcomm votes against Lexicon’s type 1 diabetes and CKD drug

For the second time in five years, an FDA advisory committee voted against endorsing the benefit-risk profile of Lexicon’s drug sotagliflozin.

The Endocrinologic and Metabolic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C. | Psychedelic Invest

VANCOUVER, British Columbia, Feb. 01, 2024 (GLOBE NEWSWIRE) — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI), a mental health care company advancing traditional

February 2, 2024

SPY ETF Analysis And how to play SPY ETF will do after inflation

July 10, 2023

Whole Genome Sequencing Boosts Diagnosis of Rare Disease in Infants

Whole genome sequencing captured almost twice as many genetic abnormalities that may be responsible for disease in infants, compared with a standard targeted test, researchers

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.